The 2016 revision of the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines provides updated recommendations for the treatment of allergic rhinitis (AR). The guidelines emphasize the use of oral H1-antihistamines, intranasal H1-antihistamines, intranasal corticosteroids, and leukotriene receptor antagonists. They also address the use of combinations of these medications and recommend specific treatments based on the severity of symptoms. The guidelines aim to improve patients' quality of life, school and work productivity, and overall health outcomes. The ARIA guidelines are developed by a panel of experts from various countries and include recommendations for both adults and children. The guidelines are based on systematic reviews of the literature and follow the GRADE approach to assess the strength of recommendations. The guidelines are intended to support clinicians, patients, and healthcare professionals in making informed decisions about the treatment of allergic rhinitis. The guidelines also highlight the importance of considering patient values and preferences, as well as the cost-effectiveness of treatments. The ARIA guidelines are regularly updated to reflect new evidence and ensure that recommendations remain current and relevant. The guidelines are used to develop integrated care pathways and are part of a broader initiative to improve the management of allergic rhinitis and its impact on asthma. The guidelines emphasize the need for rigorous systematic reviews and transparent reporting to ensure that recommendations are based on the best available evidence. The ARIA guidelines are an important resource for healthcare professionals and patients seeking information on the treatment of allergic rhinitis.The 2016 revision of the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines provides updated recommendations for the treatment of allergic rhinitis (AR). The guidelines emphasize the use of oral H1-antihistamines, intranasal H1-antihistamines, intranasal corticosteroids, and leukotriene receptor antagonists. They also address the use of combinations of these medications and recommend specific treatments based on the severity of symptoms. The guidelines aim to improve patients' quality of life, school and work productivity, and overall health outcomes. The ARIA guidelines are developed by a panel of experts from various countries and include recommendations for both adults and children. The guidelines are based on systematic reviews of the literature and follow the GRADE approach to assess the strength of recommendations. The guidelines are intended to support clinicians, patients, and healthcare professionals in making informed decisions about the treatment of allergic rhinitis. The guidelines also highlight the importance of considering patient values and preferences, as well as the cost-effectiveness of treatments. The ARIA guidelines are regularly updated to reflect new evidence and ensure that recommendations remain current and relevant. The guidelines are used to develop integrated care pathways and are part of a broader initiative to improve the management of allergic rhinitis and its impact on asthma. The guidelines emphasize the need for rigorous systematic reviews and transparent reporting to ensure that recommendations are based on the best available evidence. The ARIA guidelines are an important resource for healthcare professionals and patients seeking information on the treatment of allergic rhinitis.